Lung Cancer Screening
Overview
Authors
Affiliations
Screening for lung cancer in high-risk individuals with annual low-dose computed tomography has been shown to reduce lung cancer mortality by 20% and is recommended by multiple health care organizations. Lung cancer screening is not a specific test; it is a process that involves appropriate selection of high-risk individuals, careful interpretation and follow-up of imaging, and annual testing. Screening should be performed in the context of a multidisciplinary program experienced in the diagnosis and management of lung nodules and early-stage lung cancer.
Chen Y, Zhang Y, Chen X, Luo J, Chen Z, Zhao L Front Psychol. 2023; 14:1039501.
PMID: 37063587 PMC: 10101174. DOI: 10.3389/fpsyg.2023.1039501.
Ansar A, Lewis V, McDonald C, Liu C, Rahman M PLoS One. 2021; 16(9):e0257301.
PMID: 34506592 PMC: 8432814. DOI: 10.1371/journal.pone.0257301.
Zhou X, Liu H, Wang W, Zhao H, Wang T Int J Clin Exp Pathol. 2020; 11(9):4395-4404.
PMID: 31949836 PMC: 6962954.
Gao N, Ye B Cancer Cell Int. 2020; 20:2.
PMID: 31911754 PMC: 6942331. DOI: 10.1186/s12935-019-1065-x.
Trends in lung cancer screening in the United States, 2016-2017.
Okereke I, Nishi S, Zhou J, Goodwin J J Thorac Dis. 2019; 11(3):873-881.
PMID: 31019776 PMC: 6462682. DOI: 10.21037/jtd.2019.01.105.